Trial | NCT01031849  Report issue

Title

Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir
Análisis de Los Cambios en el Tejido Adiposo de Pacientes Con infección VIH y Lipoatrofia en Tratamiento Con análogos de nucleósidos timidínicos, Tras el Cambio a Monoterapia Con Lopinavir/Ritonavir

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Terminated

  • Intervention/Treatment

    lopinavir ...

  • Study Participants

    7
The objective is to analyse the changes in the adipose tissue hystological features and the adipogenesis gene expression and related to inflammation after 48 and 96 weeks after the change from AZT+3TC+ABC (Trizivir®) to a monotherapy treatment with LPV/r (Kaletra®)
Study Started
Feb 28
2010
Primary Completion
Oct 31
2012
Study Completion
Nov 30
2012
Last Update
Apr 08
2013
Estimate

Drug Kaletra

Each tablet of Kaletra contains 200 mg of Lopinavir and 50mg of ritonavir. The patients will take two tablets of Kaletra bid.

Kaletra, all patients Experimental

Patients will change actual treament for monotherapy LPV/r. They only will take Kaletra 2/day

Criteria 

Inclusion Criteria:

Patients infected with VIH-1, documented with a positive HIV-1 antibody test and/or positive PCR, confirmed for HIV-1 RNA.
Patients treated with a HAART that should contain AZT+3TC+ABC (Trizivir®)
Patients with an indetectable viral load, which will be defined <40 copies/mL within the last six months.
Patients with a lipoatrophy clinical evidence (which will be defined as moderate or severe, according to the Lipodystrophy Severity Grading Scale).
Men or women aged ≥ 18.
For women of childbearing potential, negative urine pregnancy test during the Screening visit.
Patients that have signed and dated the Informed consent Form prior to any Study-specific procedure.

Exclusion Criteria:

Patients with evidence of protease inhibitors failure, and/or documented evidence of protease gene resistance mutation. This evidence could be prior or during the inclusion period in the Study.
Patients who, for any reason could not be treated with LPV/r.
Cachexia, defined as an Body Mass Index <17 Kg/m2.
Pregnant or breastfeeding women, or women of childbearing potential who do not use the appropriate contraceptive method, according to the Investigator judgment.
Clinically relevant disease or condition, according to the Investigator judgment, three months prior to the patient inclusion in the Study.
Patients taking the following concomitant medication that could affect the adipocyte function or morphology, such as: insulin, steroids, anabolic steroid, anti-inflammatory medication for more than three months.
No Results Posted